1 |
SV2C
| [1] ECM-receptor interaction ECM-receptor interaction | D11842
D11842
|
Padsevonil
| [1] 149 149 |
2 |
ITGA4
| [11] PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Focal adhesion, ECM-receptor interaction, Hematopoietic cell lineage, Leukocyte transendothelial migration, Intestinal immune network for IgA production, Regulation of actin cytoskeleton, Yersinia infection, Leishmaniasis, Human papillomavirus infection, Hypertrophic cardiomyopathy | D06590
D06590
|
Firategrast
| [1] 13 13 |
3 |
ITGA4
| [11] PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Focal adhesion, ECM-receptor interaction, Hematopoietic cell lineage, Leukocyte transendothelial migration, Intestinal immune network for IgA production, Regulation of actin cytoskeleton, Yersinia infection, Leishmaniasis, Human papillomavirus infection, Hypertrophic cardiomyopathy | D06886
D06886
|
Natalizumab
| [6] 13 13, 15, 25, 46, 63, 96 |
4 |
ITGA4
| [11] PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Focal adhesion, ECM-receptor interaction, Hematopoietic cell lineage, Leukocyte transendothelial migration, Intestinal immune network for IgA production, Regulation of actin cytoskeleton, Yersinia infection, Leishmaniasis, Human papillomavirus infection, Hypertrophic cardiomyopathy | D08083
D08083
|
Vedolizumab
| [3] 94 94, 96, 97 |
5 |
ITGA4
| [11] PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Focal adhesion, ECM-receptor interaction, Hematopoietic cell lineage, Leukocyte transendothelial migration, Intestinal immune network for IgA production, Regulation of actin cytoskeleton, Yersinia infection, Leishmaniasis, Human papillomavirus infection, Hypertrophic cardiomyopathy | D10540
D10540
|
Abrilumab
| [2] 96 96, 97 |
6 |
ITGB7
| [8] PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Focal adhesion, ECM-receptor interaction, Intestinal immune network for IgA production, Regulation of actin cytoskeleton, Human papillomavirus infection, Transcriptional misregulation in cancer, Hypertrophic cardiomyopathy | D08083
D08083
|
Vedolizumab
| [3] 94 94, 96, 97 |
7 |
ITGB7
| [8] PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Focal adhesion, ECM-receptor interaction, Intestinal immune network for IgA production, Regulation of actin cytoskeleton, Human papillomavirus infection, Transcriptional misregulation in cancer, Hypertrophic cardiomyopathy | D09901
D09901
|
Etrolizumab
| [2] 96 96, 97 |
8 |
ITGB7
| [8] PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Focal adhesion, ECM-receptor interaction, Intestinal immune network for IgA production, Regulation of actin cytoskeleton, Human papillomavirus infection, Transcriptional misregulation in cancer, Hypertrophic cardiomyopathy | D10540
D10540
|
Abrilumab
| [2] 96 96, 97 |
9 |
VWF
| [6] PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Focal adhesion, ECM-receptor interaction, Platelet activation, Neutrophil extracellular trap formation, Human papillomavirus infection | D11160
D11160
|
Caplacizumab
| [1] 64 64 |
10 |
SV2B
| [1] ECM-receptor interaction ECM-receptor interaction | D11842
D11842
|
Padsevonil
| [1] 149 149 |
11 |
SV2A
| [1] ECM-receptor interaction ECM-receptor interaction | D00709
D00709
|
Levetiracetam
| [5] 2 2, 4, 6, 13, 307 |
12 |
SV2A
| [1] ECM-receptor interaction ECM-receptor interaction | D08879
D08879
|
Brivaracetam
| [2] 149 149, 309 |
13 |
SV2A
| [1] ECM-receptor interaction ECM-receptor interaction | D11842
D11842
|
Padsevonil
| [1] 149 149 |